Advertisement

Daunorubicin

  • Ines Mader
  • Patrizia E. Fürst-Weger
  • Robert M. Mader
  • Elisabeth I. Semenitz
  • Robert Terkola
  • Sabine M. Wassertheurer

Keywords

Clin Oncol Sodium Bicarbonate Doxorubicin Hydrochloride Topical Cool Extravasation Injury 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Original articles

  1. [1]
    Lawrence HJ, Goodnight SH: Dimethyl sulfoxide and extravasation of anthracycline agents. Ann Intern Med 98: 1025, 1983.PubMedCrossRefGoogle Scholar
  2. [2]
    Olver IN, Aisner J, Hament A, et al: A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol 6: 1732 1735, 1988.Google Scholar
  3. [3]
    Larson DL: What is the appropriate management of tissue extravasation by antitumor agents? Plast Reconstr Surg 75: 397–402, 1985.PubMedCrossRefGoogle Scholar
  4. [4]
    Kappel B, Hindenburg AA, Taub RN: Treatment of anthracycline extravasation — a warning against the use of sodium bicarbonate. J Clin Oncol 5: 825–826, 1987.PubMedGoogle Scholar
  5. [5]
    Jackson IT, Robinson DW: Severe tissue damage following accidental subcutaneous infusion of bicarbonate solution. Scot Med J 21: 200–201, 1976.PubMedGoogle Scholar
  6. [6]
    Gaze NR: Tissue necrosis caused by commonly used intravenous infusions. Lancet 2: 417–419, 1978.PubMedCrossRefGoogle Scholar
  7. [7]
    Dragon LH, Braine HG: Necrosis of the hand after daunorubicin infusion distal to an arteriovenous fistula. Ann Intern Med 91: 58–59, 1979.PubMedCrossRefGoogle Scholar

Secondary literature

  1. [8]
    Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245–255, 1995.PubMedCrossRefGoogle Scholar
  2. [9]
    Ignoffo RJ, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17–27, 1980. [10] Schneider G: Paravasate von Zytostatika. Diagnostik und Therapie. Aina S.Google Scholar
  3. Schneider Verlag, 6th edition: 1–17, 1999.Google Scholar
  4. [11]
    Krämer I: Onkologische Pharmazie. In: Jaehde U, Radziwill R, Mühlebach S, et al (eds) Lehrbuch der Klinischen Pharmazie. Wissenschaftliche Verlagsgesellschaft mbH, 1st edition: 253–279, 1998.Google Scholar
  5. [12]
    Dorr RT: Pharmacologic management of vesicant chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton and Lange, 2nd edition: 109–118, 1994.Google Scholar
  6. [13]
    Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 1, 2nd edition: A42–44, 1997.Google Scholar
  7. [14]
    Stanley A: Managing complications of chemotherapy. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 105–124, 1997.Google Scholar
  8. [15]
    Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.Google Scholar
  9. [16]
    Kraft A, Weinig S, Edinger M, et al: Anthrazyklin-Extravasate. Der Onkologe 6: 674–686, 2000.CrossRefGoogle Scholar
  10. [17]
    Cox RF: Managing skin damage induced by doxorubicin hydrochloride and daunorubicin hydrochloride. Am J Hosp Pharm 41: 2410–2414, 1984.PubMedGoogle Scholar
  11. [18]
    Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.PubMedCrossRefGoogle Scholar
  12. [19]
    Schneider SM, Distelhorst CW: Chemotherapy-induced emergencies. Semin Oncol 16: 572–578, 1989.PubMedGoogle Scholar

Further reading

  1. Rospond RM: Utilization of dimethyl sulfoxide for treating anthracycline extravasation. J Oncol Pharm Practice 1: 33–39, 1995.CrossRefGoogle Scholar
  2. Soble MJ, Dorr RT, Plezia P, et al: Dose-dependent skin ulcers in mice treated with DNA binding antitumor antibiotics. Cancer Chemother Pharmacol 20: 33–36, 1987.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2003

Authors and Affiliations

  • Ines Mader
    • 1
  • Patrizia E. Fürst-Weger
    • 2
  • Robert M. Mader
    • 3
  • Elisabeth I. Semenitz
    • 4
  • Robert Terkola
    • 5
  • Sabine M. Wassertheurer
    • 6
  1. 1.Austrian Breast and Colorectal Cancer Study GroupViennaAustria
  2. 2.SMZ FloridsdorfKrankenhaus und GeriatriezentrumViennaAustria
  3. 3.Clinical Division of Oncology, Department of Medicine IUniversity HospitalViennaAustria
  4. 4.AnstaltsapothekeLandeskrankenhaus — Universitätskliniken InnsbruckAustria
  5. 5.Kaiser-Franz-Josef HospitalViennaAustria
  6. 6.Apotheke LKH-Univ.-Klinikum GrazAustria

Personalised recommendations